Therefore, we aimed to investigate whether the combination of BLU-554, a highly specific inhibitor of FGFR4 25, and KX2-391, a novel inhibitor of SRC kinase 26, could affect ELF4-mediated CRC migration and invasion. Here, ELF4 is linked to colorectal carcinoma.